Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Herz
Erschienen in: Herz 6/2015

01.09.2015 | Original article

Relationship between serum visfatin levels and coronary slow-flow phenomenon

verfasst von: Huseyin Altug Cakmak, MD, Serkan Aslan, MD, Ahmet Arif Yalcin, MD, Ibrahim Faruk Akturk, MD, Burce Yalcin, MD, Fatih Uzun, MD, Derya Ozturk, MD, Mehmet Erturk, MD, Mehmet Gul, MD

Erschienen in: Herz | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Increased levels of visfatin, a novel adipocytokine, are reported in atherosclerosis, obesity, and type 2 diabetes. The aim of the present study was to investigate the relationship between coronary slow flow (CSF) and visfatin in patients undergoing elective coronary angiography for suspected coronary artery disease.

Patients and methods

A total of 140 recruited participants (90 patients with CSF and 50 controls) were divided into two groups according to their coronary flow rates. Coronary flow was quantified by thrombolysis in myocardial infarction (TIMI) frame count (TFC).

Results

Serum visfatin levels were higher in the CSF group than in the control group (3.29 ± 1.11 vs. 2.70 ± 1.08 ng/ml, p = 0.003). A significant correlation was found between TFC and visfatin (r = 0.535, p < 0.001). The area under the receiver operating characteristic curve was 0.720 (95 % confidence interval, 0.622–0.817, p < 0.001) for visfatin in the diagnosis of CSF. If a cut-off value of 2.59 ng/ml was used, higher levels of visfatin could predict the presence of CSF with 78.9 % sensitivity and 64.0 % specificity.

Conclusion

Visfatin levels might be a useful biomarker for predicting CSF in patients undergoing diagnostic coronary angiography.
Literatur
1.
Cutri N, Zeitz C, Kucia AM, Beltrame JF (2011) ST/T wave changes during acute coronary syndrome presentation in patients with the coronary slow flow phenomenon. Int J Cardiol 146:457–458CrossRefPubMed
2.
Arbel Y, Rind E, Banai S et al (2012) Prevalence and predictors of slow flow in angiographically normal coronary arteries. Clin Hemorheol Microcirc 52:5–14PubMed
3.
Hawkins BM, Stavrakis S, Rousan TA et al (2012) Coronary slow flow—prevalence and clinical correlations. Circ J 76:936–942CrossRefPubMed
4.
Horjeti B, Goda A (2012) Acute ischemiamanifestation in a patient with coronary slowflow phenomenon. J Electrocardiol 45:277–279CrossRefPubMed
5.
Surgit O, Erturk M, Akgul O et al (2014) The effect of slow coronary artery flow on microvolt T-Wave alternans. Acta Cardiol Sin 30:190–196
6.
Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430CrossRefPubMed
7.
Kim SR, Bae SK, Choi KS et al (2007) Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 357:150–156CrossRefPubMed
8.
Takebayashi K, Suetsugu M, Wakabayashi S et al (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56:451–458CrossRefPubMed
9.
Dahl TB, Yndestad A, Skjelland M et al (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization. Circulation 115:972–980CrossRefPubMed
10.
Brentano F, Schorr O, Ospelt C et al (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56:2829–2839CrossRefPubMed
11.
Chen MP, Chung FM, Chang DM et al (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295–299CrossRefPubMed
12.
Moschen AR, Kaser A, Enrich B et al (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748–1758CrossRefPubMed
13.
Brentano F, Schorr O, Ospelt C et al (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56:2829–2839CrossRefPubMed
14.
Kadoglou NP, Sailer N, Moumtzouoglou A et al (2010) Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 118:75–80CrossRefPubMed
15.
Ucgun T, Başar C, Memişoğulları R et al (2014) Serum visfatin and omentin levels in slow coronary flow. Rev Port Cardiol 33:789–794PubMed
16.
James PA, Oparil S, Carter BL et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520CrossRefPubMed
17.
Kadoglou NP, Iliadis F, Angelopoulou N et al (2009) Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications 23:160–166CrossRefPubMed
18.
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMed
19.
European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G et al (2011) ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818CrossRefPubMed
20.
Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879–888CrossRefPubMed
21.
Yilmaz H, Demir I, Uyar Z (2008) Clinical and coronary angiographiccharacteristics of patients with coronary slow flow. Acta Cardiol 63:579–584CrossRefPubMed
22.
Dogan M, Akyel A, Cimen T et al (2013) Relationship between neutrophil to lymphocyte ratio and slow coronary flow. Clin Appl Thromb Hemost 21:251-254
23.
Aksan G, Soylu K, Aksoy O et al (2014) The relationship between neutrophil gelatinase-associated lipocalin levels and the slow coronary flow phenomenon. Coron Artery Dis 25:505–509CrossRefPubMed
24.
Canga A, Cetin M, Kocaman SA et al (2013) Increased serum resistin levels in patients with coronary slow-flow phenomenon. Herz 38:773–778CrossRefPubMed
25.
Mangieri E, Macchiarelli G, Ciavolella M et al (1996) Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 37:375–381CrossRefPubMed
26.
Cin VG, Pekdemir H, Camsar A et al (2003) Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 44:907–919CrossRefPubMed
27.
Sezgin AT, Sigirci A, Barutcu I et al (2003) Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 14:155–161CrossRefPubMed
28.
Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E (1972) Angina pectoris and slow flow velocity of dye in coronary arteries—a new angio-graphic finding. Am Heart J 84:66–71CrossRefPubMed
29.
Mangieri E, Macchiarelli G, Ciavolella M et al (1996) Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 37:375–381CrossRefPubMed
30.
Pekdemir H, Polat G, Cin VG et al (2004) Elevated plasma endothelin-1 levels in coronary sinüs during rapid right atrial pacing in patients with slow coronary flow. Int J Cardiol 97:35–41CrossRefPubMed
31.
De Bruyne B, Fearon WF, Pijls NH et al (2014) FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371:1208–1217CrossRefPubMed
32.
Yildiz A, Gur M, Yilmaz R et al (2008) Association of paraoxonase activity and coronary blood flow. Atherosclerosis 197:257–263CrossRefPubMed
33.
Enli Y, Türk M, Akbay R (2008) Oxidative stress parameters in patients with slow coronary flow. Adv Ther 25:37–44CrossRefPubMed
34.
Li JJ, Qin XW, Li ZC et al (2007) Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta 385:43–47CrossRefPubMed
35.
Barutcu I, Sezgin AT, Sezgin N et al (2007) Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow. Angiology 58:401–407CrossRefPubMed
36.
Kaya H, Ertaş F, İslamoğlu Y et al (2014) Association between neutrophil to lymphocyte ratio and severity of coronary artery disease. Clin Appl Thromb Hemost 20:50–54CrossRefPubMed
37.
Shen XH, Chen Q, Shi Y, Li HW (2010) Association of neutrophil/lympho-cyte ratio with long-term mortalityafter ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J (Engl) 123:3438–3443
38.
Erturk M, Cakmak HA, Surgit O et al (2014) The predictive value of elevated neutrophil to lymphocyte ratio for long-term cardiovascular mortality in peripheral arterial occlusive disease. J Cardiol 64:371–376CrossRefPubMed
39.
Li JJ, Wu YJ, Qin XW (2006) Should slow coronary flow be considered as a coronary syndrome? Med Hypotheses 66:953–956CrossRefPubMed
40.
Erdoğan D, Çalışkan M, Güllü H et al (2007) Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis 191:168–174CrossRefPubMed
41.
Li JJ, Xu B, Li ZC et al (2006) Is slow coronary flow associated with inflammation? Med Hypotheses 66:504–508CrossRefPubMed
42.
Wang X, Geng LL, Nie SP (2010) Coronary slow flow phenomenon: a local or systemic disease? Med Hypotheses 75:334–337CrossRefPubMed
43.
Wozakowska-Kapłon B, Niedziela J, Krzyzak P, Stec S (2009) Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias. Cardiol J 16:462–468PubMed
44.
Saya S, Hennebry TA, Lozano P et al (2008) Coronary slow flow phenomenon and risk for sudden cardiac death due to ventricular arrhythmias: a case report and review of literature. Clin Cardiol 31:352–355CrossRefPubMed
45.
Lyon CJ, Law RE, Hsueh WA (2003) Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144:2195–2200CrossRefPubMed
46.
Fragasso G, Chierchia SL, Arioli F et al (2009) Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: long-term clinical and functional prognosis. Int J Cardiol 137:137–144CrossRefPubMed
47.
Turkmen M, Barutcu I, Esen AM et al (2004) Comparison of exercise QRS amplitude changes in patients with slow coronary flow versus significant coronary stenosis. Jpn Heart J 45:419–428CrossRefPubMed
48.
Sezgin AT, Topal E, Barutcu I et al (2005) Impaired left ventricle filling in slow coronary flow phenomenon: an echo-Doppler study. Angiology 56:397–401CrossRefPubMed
49.
Watson PS, Hadjipetrou P, Cox SV et al (1999) Angiographic and clinical outcomes following acute infarct angioplasty on saphenous vein grafts. Am J Cardiol 83:1018–1021CrossRefPubMed
50.
Zhou H, He XY, Zhuang SW et al (2014) Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med 5:96–102PubMedCentralCrossRefPubMed
51.
Kirma C, Izgi A, Dundar C et al (2008) Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J 72:716–721CrossRefPubMed
52.
Romacho T, Sánchez-Ferrer CF, Peiró C (2013) Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013:946427PubMedCentralPubMed
Metadaten
Titel
Relationship between serum visfatin levels and coronary slow-flow phenomenon
verfasst von
Huseyin Altug Cakmak, MD
Serkan Aslan, MD
Ahmet Arif Yalcin, MD
Ibrahim Faruk Akturk, MD
Burce Yalcin, MD
Fatih Uzun, MD
Derya Ozturk, MD
Mehmet Erturk, MD
Mehmet Gul, MD
Publikationsdatum
01.09.2015
Verlag
Urban & Vogel
Erschienen in
Herz / Ausgabe 6/2015
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-015-4313-4

Weitere Artikel der Ausgabe 6/2015

Herz 6/2015 Zur Ausgabe

Original article

Recent-onset dilated cardiomyopathy associated with Borrelia burgdorferi infection

Main Topic

Progression of coronary artery disease

Editorial

Progression der koronaren Atherosklerose

Main Topic

OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease

CME

Management der arteriellen Hypertonie

Original article

Neuromuscular comorbidity, heart failure, and atrial fibrillation as prognostic factors in left ventricular hypertrabeculation/noncompaction

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen